Currently out of the existing stock ratings of Kaveri Pohlman, 54 are a BUY (93.1%), 4 are a HOLD (6.9%).

Kaveri Pohlman

Work Performance Price Targets & Ratings Chart

Analyst Kaveri Pohlman, currently employed at BTIG, carries an average stock price target met ratio of 34.35% that have a potential upside of 41.41% achieved within 157 days.

Kaveri Pohlman’s has documented 105 price targets and ratings displayed on 21 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on PTGX, Protagonist Therapeutics at 07-Apr-2026.

Wall Street Analyst Kaveri Pohlman

Analyst best performing recommendations are on CMPI (CHECKMATE PHARMACEUTICALS).
The best stock recommendation documented was for CMPI (CHECKMATE PHARMACEUTICALS) at 3/30/2022. The price target of $9 was fulfilled within 20 days with a profit of $5.78 (179.5%) receiving and performance score of 89.75.

Average potential price target upside

of $195.63 (86.97%) on MRSN (MERSANA THERAPEUTICS).
of $14.47 (26.95%) on PTGX (PROTAGONIST THERAPEUTICS).
of $8.54 (76.7%) on CGEM (CULLINAN ONCOLOGY LLC).

CTMX CytomX Therapeutics CMPI Checkmate Pharmaceuticals MGNX MacroGenics ONCS OncoSec Medical MRSN Mersana Therapeutics BCAB Bioatla GMAB Genmab AS NUVB Nuvation Bio RCUS Arcus Biosciences REPL Replimune Group CGEM Cullinan Oncology LLC XNCR Xencor RAPT RAPT Therapeutics STTK Shattuck Labs JANX Janux Therapeutics CRGX CARGO Therapeutics, Common Stock ERAS Erasca MLTX MoonLake Immunotherapeutics PTGX Protagonist Therapeutics SONN Sonnet Biotherapeutics Holdings TRVI Trevi Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Joseph Catanzaro (MIZUHO)